Surveillance of Resistance to New Antibiotics in an Era of Limited Treatment Options

被引:2
作者
Morel, Chantal M. [1 ,2 ,3 ]
de Kraker, Marlieke E. A. [2 ,4 ]
Harbarth, Stephan [2 ,4 ,5 ]
机构
[1] Univ Geneva Hosp, Geneva, Switzerland
[2] Fac Med, Geneva, Switzerland
[3] Univ Hosp Bonn, Inst Hyg & Publ Hlth, Bonn, Germany
[4] Univ Geneva Hosp, Infect Control Programme, Geneva, Switzerland
[5] Univ Geneva Hosp, WHO Collaborating Ctr Patient Safety, Geneva, Switzerland
基金
瑞士国家科学基金会;
关键词
resistance surveillance; antibiotics; antimicrobial resistance; antimicrobial susceptibility; early warning systems; CARE-ASSOCIATED INFECTIONS; ANTIMICROBIAL RESISTANCE; STAPHYLOCOCCUS-AUREUS; RECOMMENDATIONS; SUSCEPTIBILITY; PNEUMONIAE; BACTERIA; SYSTEMS; EUROPE;
D O I
10.3389/fmed.2021.652638
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As with any health threat, our ability to respond to the emergence and spread of antimicrobial resistance depends on our ability to understand the scale of the problem, magnitude, geographical spread, and trends over time. This is especially true for resistance emergence to newer antibiotics coming to the market as last-resort treatments. Yet current antibiotic surveillance systems are limited to monitoring resistance to commonly prescribed drugs that have been on the market for a long time. This qualitative study determined the essential elements and requirements of antimicrobial resistance surveillance for new antibiotics based on literature review, interviews and expert consensus. After an extensive mapping exercise, 10 experts participated in a modified Delphi consultation to identify consensus on all elements required for surveillance of resistance to novel antibiotics. The main findings indicate that there is a need for a two-phase system; an early alert system transitioning to routine surveillance, led by the public sector to gather and share essential data on resistance to newer antibiotics in a transparent manner. The system should be decentralized, run largely from national level, but be coordinated by an arm of an existing international public health institution. Priority should be given to monitoring emergence of resistance among already multi-drug resistant pathogens causing infections, over a broader selection of pathogens to maximize clinical impact. In conclusion, we cannot rely on current AMR surveillance systems to monitor resistance emergence to new antibiotics. A new, public system should be set-up, starting with a focus on detecting resistance emergence, but expanding to a more comprehensive surveillance as soon as there is regional spread of resistance to the new antibiotic. This article provides a framework based on expert agreement, which could guide future initiatives.
引用
收藏
页数:10
相关论文
共 47 条
  • [1] [Anonymous], 2013, EUROSURVEILLANCE
  • [2] [Anonymous], EU PROT HARM MON ANT
  • [3] [Anonymous], 1998, ANTIMICROBIAL RESIST
  • [4] Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings
    Ashley, Elizabeth A.
    Shetty, Nandini
    Patel, Jean
    van Doorn, Rogier
    Limmathurotsakul, Direk
    Feasey, Nicholas A.
    Okeke, Iruka N.
    Peacock, Sharon J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (03) : 541 - 546
  • [5] An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000
    Ashley, Elizabeth A.
    Recht, Judith
    Chua, Arlene
    Dance, David
    Dhorda, Mehul
    Thomas, Nigel V.
    Ranganathan, Nisha
    Turner, Paul
    Guerin, Philippe J.
    White, Nicholas J.
    Day, Nicholas P.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (07) : 1737 - 1749
  • [6] Surveillance of antimicrobial resistance - what, how and whither?
    Bax, R
    Bywater, R
    Cornaglia, G
    Goossens, H
    Hunter, P
    Isham, V
    Jarlier, V
    Jones, R
    Phillips, I
    Sahm, D
    Senn, S
    Struelens, M
    Taylor, D
    White, A
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (06) : 316 - 325
  • [7] Recommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position Paper
    Cohen, Adam L.
    Calfee, David
    Fridkin, Scott K.
    Huang, Susan S.
    Jernigan, John A.
    Lautenbach, Ebbing
    Oriola, Shannon
    Ramsey, Keith M.
    Salgado, Cassandra D.
    Weinstein, Robert A.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (10) : 901 - 913
  • [8] European recommendations for antimicrobial resistance surveillance
    Cornaglia, G
    Hryniewicz, W
    Jarlier, V
    Kahlmeter, G
    Mittermayer, H
    Stratchounski, L
    Baquero, F
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (04) : 349 - 383
  • [9] Phenotypic Resistance to Antibiotics
    Corona, Fernando
    Martinez, Jose L.
    [J]. ANTIBIOTICS-BASEL, 2013, 2 (02): : 237 - 255
  • [10] Optimal use of antibiotic resistance surveillance systems
    Critchley, IA
    Karlowsky, JA
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (06) : 502 - 511